|
| 28 October 2016 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Share Options
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that on 27th October 2016 it awarded the following options over ordinary shares of the Company to certain Directors.
| Name | Position | Number of Share Options Awarded | Exercise price per Share | Date of vesting | Percentage of issued ordinary share capital |
| Andrew Franklin | Chief Financial Officer | 155,000 | 47.50 | October 2018 | 0.033 |
| Andrew Franklin | Chief Financial Officer | 400,000 | 47.50 | October 2020 | 0.085 |
| Peter Butterfield | Deputy Chief Executive Officer | 200,000 | 47.50 | October 2018 | 0.042
|
| Peter Butterfield | Deputy Chief Executive Officer | 1,000,000 | 47.50 | October 2020 | 0.212
|
The vesting of the awards that are scheduled to vest in October 2018 is subject to continued employment and the vesting of the awards that are scheduled to vest in October 2020 is subject to continued employment and the satisfaction of certain performance conditions.
For further information:
| Alliance Pharma plc | + 44 (0) 1249 466966 |
| John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer |
|
| Sarah Robinson, Company Secretary |
|
| www.alliancepharma.co.uk |
|
| Buchanan | + 44 (0) 20 7466 5000 |
| Mark Court / Sophie Cowles / Jane Glover |
|
|
|
|
| Numis Securities Limited | + 44 (0) 20 7260 1000 |
| Nominated Adviser: Michael Meade / Freddie Barnfield |
|
| Corporate Broking: James Black / Toby Adcock |
|
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international specialty pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
| a)
| Name
| 1. Andrew Franklin2. Peter Butterfield
| ||||
| 2
| Reason for the notification
| |||||
| a)
| Position/status
| 1. Chief Financial Officer2. Deputy Chief Executive Officer | ||||
| b)
| Initial notification /Amendment
| Initial | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
| a)
| Name
| Alliance Pharma plc | ||||
| b)
| LEI
| n/a | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
| a)
| Description of the financial instrument, type of instrument
Identification code
| Options to subscribe for new ordinary shares of 1p each
ISIN: GB0031030819
| ||||
| b)
| Nature of the transaction
| Grant of options | ||||
| c)
| Price(s) and volume(s)
|
| ||||
| d)
| Aggregated information
- Aggregated volume
- Price
| Total 1,755,000 options granted at a price of 47.5p per share
| ||||
| e)
| Date of the transaction
| 27 October 2016 | ||||
| f)
| Place of the transaction
| Outside of trading venue | ||||